To that extent, the availability of comparable active ingredients may paradoxically be artificially limited, because the potential supplier countries could be unwilling to undermine their profitable relations with the R&D-based pharmaceutical companies, and no other sources of key active ingredients may possess the technical skills and abilities to produce them. The Financial Times (online edition), 16 August 2006, referring to a top WHO official addressing the August 2006 International Aids Conference at Toronto. This Decision was based on Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, which refers to the difficulties of those WTO members with insufficient domestic pharmaceutical manufacturing capacities to make effective use of compulsory licensing.